Wedbush Equities Analysts Cut Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at Wedbush decreased their FY2025 earnings per share estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.98) for the year, down from their prior estimate of ($0.97). Wedbush currently has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.96) EPS and FY2028 earnings at ($0.89) EPS.

TCRX has been the topic of a number of other research reports. Barclays cut their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Thursday. Finally, Needham & Company LLC lowered their target price on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and an average target price of $9.20.

TScan Therapeutics Trading Down 4.8 %

Shares of TScan Therapeutics stock opened at $1.98 on Monday. The firm’s 50 day moving average is $2.41 and its 200 day moving average is $3.99. The firm has a market capitalization of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. TScan Therapeutics has a 1 year low of $1.82 and a 1 year high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Institutional Trading of TScan Therapeutics

Institutional investors have recently modified their holdings of the business. Heck Capital Advisors LLC bought a new position in TScan Therapeutics during the 4th quarter worth $61,000. Woodline Partners LP raised its position in shares of TScan Therapeutics by 6.7% during the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after acquiring an additional 7,282 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of TScan Therapeutics in the fourth quarter worth approximately $59,000. Tang Capital Management LLC bought a new stake in TScan Therapeutics in the fourth quarter valued at approximately $358,000. Finally, Shay Capital LLC acquired a new stake in TScan Therapeutics during the 4th quarter valued at approximately $65,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.